| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 08/22/2002 | WO2002064543A2 Novel succinate salt of o-desmethyl-venlafaxine |
| 08/22/2002 | WO2002064165A1 Cell proliferation inhibitors comprising ets transcription factor or gene encoding the same |
| 08/22/2002 | WO2002064164A1 Gm-csf and/or defensin protein expression regulators in epithelial cells comprising ets transcription factor or gene encoding the same |
| 08/22/2002 | WO2002064160A2 Pharmaceutical compositions which inhibit vascular proliferation and method of use thereof |
| 08/22/2002 | WO2002064151A1 Acrochordon alleviation |
| 08/22/2002 | WO2002064146A1 4-fluoro-n-indan-2-yl benzamide and its use as pharmaceutical |
| 08/22/2002 | WO2002064142A1 Farnesyl protein transferase inhibitor combinations with antiestrogen agents |
| 08/22/2002 | WO2002064140A1 Thrombin inhibitors |
| 08/22/2002 | WO2002064139A1 Treatment of parkinson's disease by the combined action of a compound with neurotrophic activity and a compound enhancing the dopamine activity |
| 08/22/2002 | WO2002064138A1 Preparations and use of an ah receptor ligand, 2-(1'h-indole-3'-carbonyl)-thiazole-4-carboxylic acid methyl ester |
| 08/22/2002 | WO2002064136A2 Malonyl-coa decarboxylase inhibitors useful as metabolic modulators |
| 08/22/2002 | WO2002064135A1 Heterocyclic inhibitors of glycine transporter 2 |
| 08/22/2002 | WO2002064133A1 Preparations for controlling concentration in blood |
| 08/22/2002 | WO2002064132A2 Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability |
| 08/22/2002 | WO2002064130A1 Proliferative activator receptor (ppar) compounds |
| 08/22/2002 | WO2002064129A2 Compositions of biochemical compounds involved in bioenergy metabolism of cells |
| 08/22/2002 | WO2002064127A1 Methods and clinical devices for the inhibition or prevention of mammalian cell growth |
| 08/22/2002 | WO2002064119A1 Tablets quickly disintegrated in oral cavity |
| 08/22/2002 | WO2002064094A2 2-aryloxy-2-arylalkanoic acids for diabetes and lipid disorders |
| 08/22/2002 | WO2002064092A2 Method for evaluating therapeutic efficacy |
| 08/22/2002 | WO2002064085A2 Treatment of neurological dysfunction comprising fructopyranose sulfamates and erythropoietin |
| 08/22/2002 | WO2002064080A2 Matrix metalloproteinase inhibitors |
| 08/22/2002 | WO2002063982A1 Composition and method for smoke detoxification |
| 08/22/2002 | WO2002063961A1 Composition and methods for modulation of vascular structure and/or function |
| 08/22/2002 | WO2002048112A3 7-heterocyclyl quinoline and thieno[2,3-b]pyridine derivatives useful as antagonists of gonadotropin releasing hormone |
| 08/22/2002 | WO2002045652A3 Tyrosine kinase inhibitors |
| 08/22/2002 | WO2002040471A3 Tetrahydrobenzazepine derivatives useful as modulators of dopamine d3 receptors (antipsychotic agents) |
| 08/22/2002 | WO2002040008A3 Treatment of sexual dysfunction with non peptide bombesin receptor antagonists |
| 08/22/2002 | WO2002036587A3 Process for the production of 4-quinazolinylpiperazin-1-carboxylic acid phenylamides |
| 08/22/2002 | WO2002032869A3 Substituted heterocyclic compounds for treating multidrug resistance |
| 08/22/2002 | WO2002024204A3 Treatment of diabetes mellitus by inhibition of mitochondrial calcium/sodium antiporter |
| 08/22/2002 | WO2002015959A3 Compounds and compositions for delivering active agents |
| 08/22/2002 | WO2002008250A3 Ghrelin antagonists |
| 08/22/2002 | WO2002004412A3 Tyrosine derivatives as phosphatase inhibitors |
| 08/22/2002 | WO2002004008A3 Methods of therapy with thrombin derived peptides |
| 08/22/2002 | WO2001089586A3 Tc and re carbonyl complexes for pertechnetate and perrhenate |
| 08/22/2002 | WO2001085204A3 Therapeutic method and composition utilizing antigen-antibody complexation and presentation by dendritic cells |
| 08/22/2002 | WO2001085203A3 Therapeutic method and composition utilizing antigen-antibody complexation and presentation by dendritic cells |
| 08/22/2002 | WO2001042506A9 T1 receptor-like ligand ii and uses thereof |
| 08/22/2002 | WO2000038706A9 Methods for treating cancer and for mediating chemotaxis of dendritic cells |
| 08/22/2002 | WO2000035423A9 Biodegradable polymer encapsulated serotonin receptor antagonist and method for preparing the same |
| 08/22/2002 | WO2000033979A9 Apparatus for separating particles of cohesive material according to size and process |
| 08/22/2002 | WO2000033865A9 Methods of inhibiting ectopic calcification |
| 08/22/2002 | WO2000023092A9 Contulakin-g, analogs thereof and uses therefor |
| 08/22/2002 | WO1999063992A9 Novel calcium channel drugs and uses |
| 08/22/2002 | US20020116069 Injectable implants for tissue augmentation and restoration |
| 08/22/2002 | US20020115858 Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use |
| 08/22/2002 | US20020115853 6-(3-nitrophenyl)-3H-benzooxazol-2-one for example; contraceptives, treating hormone dependent tumors, endometriosis; progesterone receptor agonists and antagonists |
| 08/22/2002 | US20020115843 Nucleotide sequences for use in the treatment of viral diseases, hypertension and coagulation defects |
| 08/22/2002 | US20020115826 Enzyme inhibitor for use for use in the treatment of cell proliferative defects |
| 08/22/2002 | US20020115825 Peptide for use in the treatment of gastrointestinal inflammation and defects of the blood brain barrier |
| 08/22/2002 | US20020115716 Oral low dose butyrate compositions |
| 08/22/2002 | US20020115715 Amine and amide derivatives as ligands for the neuropeptide Y Y5 receptor useful in the treatment of obesity and other disorders |
| 08/22/2002 | US20020115709 Atorvastatin hemi-calcium form VII |
| 08/22/2002 | US20020115701 Have antipyretic action, analgesic action, antiinflammatory action, and particularly, selective inhibitory action on cyclooxygenase-2; ketomethylene intermediates |
| 08/22/2002 | US20020115690 Free of alcohol and propylene glycol; surfactant; polyethylene glycol solvent having a mean molecular weight of greater than 300 but lower than 600 |
| 08/22/2002 | US20020115684 2, 7-naphthyridine derivatives |
| 08/22/2002 | US20020115681 Anticholinergics which have a long-lasting effect, such as glycopyrronium bromide, tiotropium bromide or an ester of bi-or tricyclic amino alcohol such as a nortropanol |
| 08/22/2002 | US20020115680 Anticholinergics which may be used as medicaments as well as processes for preparing them |
| 08/22/2002 | US20020115679 N-acyl- or N-sulfonylpiperidine substituted tricyclic benzocycloheptenepyridine derivatives |
| 08/22/2002 | US20020115676 Therapy for andropause using estrogen agonists / antagonists and testosterone |
| 08/22/2002 | US20020115670 1-Aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands |
| 08/22/2002 | US20020115667 Treatment of disorders associated with glycolipid accumulation, such as Niemann-Pick Type C disease by administering an inhibitor of glucosylceramide synthesis, such as N-butyldeoxynojirimycin |
| 08/22/2002 | US20020115661 Method for treating chronic obstructive pulmonary disease |
| 08/22/2002 | US20020115656 Administering 2-(1-(3-(5-Acetyl-3-(4-chloro-phenyl)-4,5,6,7-tetrahydro-pyrazolo-(4,3 -c)pyridin-1-yl)-2-hydroxy-propyl)-piperidin-4-ylamino)-benzonitrile for inhibiting cathepsins; for treating atopic diseases |
| 08/22/2002 | US20020115653 Retinoic acid mimetic anilides |
| 08/22/2002 | US20020115651 New hydroxyindoles, their use as inhibitors of phosphodiesterase 4 and processes for their preparation |
| 08/22/2002 | US20020115645 Stabilized aqueous suspensions for parenteral use |
| 08/22/2002 | US20020115643 Such as enantiomorphs of 4-fluorostyryl-2,3,4,5,6-pentafluorobenzylsulfone; antiproliferative/anticancer agents |
| 08/22/2002 | US20020115641 Compositions and methods for enhancing paracellular permeability across epithelial and endothelial barriers |
| 08/22/2002 | US20020115631 Human bad polypeptides, encoding nucleic acids and methods of use |
| 08/22/2002 | US20020115626 Comparing the expression of the nucleic acid encoding an antileuko-protease polypeptide of a cell population to the expression of a nucleic acid encoding the same peptide in an inflammation positive reference profile; enzyme inhibitors |
| 08/22/2002 | US20020115621 Macrolide antibiotics |
| 08/22/2002 | US20020115617 Methods for the prevention and / or the treatment of glutamate cytotoxicity |
| 08/22/2002 | US20020115616 Inhibit beta-secretase to reduce beta amyloid peptide concentrations and reduce the amyloid plaques and neuro-fibrillary tangles; Alzheimer's disease; stroke; Down' syndrome; amyotrophic lateral sclerosis; brain disorders |
| 08/22/2002 | US20020115603 Methods and compositions for the treatment of peripheral artery disease |
| 08/22/2002 | US20020115600 Inhibitors of memapsin 2 and use thereof |
| 08/22/2002 | US20020115594 Peptide antagonists at glutamate and NMDA receptors |
| 08/22/2002 | US20020115588 Dry powder of parathyroid hormone suitable for inhalation of specified particle size in diameters; treating osteoporosis |
| 08/22/2002 | US20020115223 In vitro system for determining formation of abeta amyloid |
| 08/22/2002 | US20020115187 Nucleotide sequences coding enzymatic polypeptide for use in the treatment of arthritis and cancer; for use as antiscarring agent |
| 08/22/2002 | US20020115186 Peptide for use in the diagnosis, prevention, and treatment of inflammation, cancer, arteriosclerosis and degenerative defects |
| 08/22/2002 | US20020115176 Polypeptide for use in the diagnosis and treatment of asthma, and respiratory disorders |
| 08/22/2002 | US20020115166 Peptide for use in the treatment of pancreatic defects |
| 08/22/2002 | US20020115156 Connective tissue growth factor for use in the treatment of cancer, fibrotic defects and atherosclerosis; for use as wound healing agents |
| 08/22/2002 | US20020115120 Controlling polypetide activity in cell; obtain cell, incubate with modulator, monitor gene expression and protein activity |
| 08/22/2002 | US20020115109 Compositions and methods for diagnosing/treating disease based on beta-catenin/transcription factor interactions |
| 08/22/2002 | US20020115081 Nucleotide sequences coding polypeptide for use in the the treatament of cardiovasculAR disorders |
| 08/22/2002 | US20020114848 Methods for regulating levels of zinc, cadmium and calcium in humans and for diagnosing, or screening for the risk of developing, diseases associated with abnormal levels of cadmium, zinc and calcium in body fluids and tissues |
| 08/22/2002 | US20020114836 Methods for making sustained-release pharmaceutical compositions of ergot alkaloids having improved bioavailability and compositions thereof |
| 08/22/2002 | US20020114812 Preparing cells as cancer therapy for administration to a subject with cancer comprising culturing cells in the presence of an macrophage migration inhibitory factor antagonist |
| 08/22/2002 | US20020114809 Restore cancer-suppressing functions to neoplastic cells through DNA hypomethylation |
| 08/22/2002 | US20020114793 Methods for inducing the differentiation of monocytes into functional dendritic cells and immunotherapeutic compositions including such dendritic cells |
| 08/22/2002 | US20020114781 Interleukin antagonists for suppressing autoimmune respone via reducing number of antigen-reactive lymphocytes; treatment of rheumatic diseases |
| 08/22/2002 | US20020114772 Methods of modulating hair growth |
| 08/22/2002 | US20020114770 For skin lightening or depigmentation; works by inhibiting tyrosinase in humans; kits |
| 08/22/2002 | DE10108215A1 Pharmazeutische Kombination von Antagonisten von Angiotensin II und Hemmern von Angiotensin II konvertierendem Enzym A pharmaceutical combination of antagonists of angiotensin II inhibitors and angiotensin II converting enzyme |
| 08/22/2002 | DE10100238A1 Verfahren zur Vorhersage des Gefährdungspotentials für Karzinomerkrankungen und entzündliche Darmerkrankungen und zugehörige Tests A method for predicting the risk potential for cancer diseases and inflammatory bowel disease and related tests |
| 08/22/2002 | CA2856986A1 Post-partum mammalian placenta, its use and placental stem cells therefrom |
| 08/22/2002 | CA2666611A1 Novel succinate salt of o-desmethyl-venlafaxine |